Armando Lucrezia Greta, Miglio Gianluca, Baroetto Parisi Raffaella, Esiliato Mariangela, Rolando Cristina, Vinciguerra Valeria, Diarassouba Abdoulaye, Cena Clara
Department of Drug Science and Technology, University of Turin, Via Pietro Giuria 11, 10125 Turin, Italy.
Competence Center of Scientific Computing C3S, University of Turin, Corso Svizzera 185, 10149 Turin, Italy.
Healthcare (Basel). 2023 Jun 5;11(11):1655. doi: 10.3390/healthcare11111655.
Due to its prevalence and socio-economic burden on health systems, diabetes mellitus (DM) is considered a major health emergency. This retrospective, observational study aimed to describe a population of DM-naïve patients of the Local Health Authority (LHA) ASL TO4 Regione Piemonte and the prescriptive behavior of LHA general practitioners. Drug dispensing data collected between January 2018 and December 2021 was analyzed. Adult patients were included if they received their first prescription for an antidiabetic drug (AD) in 2019 and had ≥2 prescriptions/year of ADs during the follow-up. Patients who started antidiabetic therapy with metformin were selected to investigate comorbidities, medication adherence, and first treatment intensification. Comorbidities were identified through a modified version of the Rx-Risk Index; adherence was measured as the continuous measure of medication availability (CMA). Among 1927 DM-naïve patients, 1361 started therapy with metformin. Most of them received drugs related to cardiovascular diseases, hypertension, and infectious diseases during the study period. Median CMA was 58.8%, with the majority of patients being partially adherent to ADs (40 ≤ CMA < 80). Initial antidiabetic therapy was mostly modified (switch, add-on) with SGLT-2 inhibitors and sulfonylureas. These findings help to identify areas of intervention to improve the use of ADs in the LHA.
由于糖尿病(DM)的普遍性及其对卫生系统造成的社会经济负担,它被视为一项重大的卫生紧急情况。这项回顾性观察研究旨在描述皮埃蒙特地区阿斯利托4地方卫生局(LHA)未患糖尿病患者群体以及LHA全科医生的处方行为。对2018年1月至2021年12月期间收集的药品配药数据进行了分析。纳入的成年患者需满足在2019年首次开具抗糖尿病药物(AD)处方且在随访期间每年有≥2张AD处方。选择开始使用二甲双胍进行抗糖尿病治疗的患者来调查合并症、用药依从性和首次治疗强化情况。通过改良版的Rx风险指数确定合并症;用药依从性通过药物可及性连续测量(CMA)来衡量。在1927名未患糖尿病的患者中,1361人开始使用二甲双胍治疗。在研究期间,他们中的大多数人接受了与心血管疾病、高血压和传染病相关的药物治疗。CMA中位数为58.8%,大多数患者对AD药物部分依从(40≤CMA<80)。初始抗糖尿病治疗大多采用钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂和磺脲类药物进行调整(换药、加药)。这些发现有助于确定干预领域,以改善LHA中AD药物的使用情况。